Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

• Status: Completed
• Trial end date: 2018-07-25
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN® (bimatoprost) 0.01%.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Patients with Primary open angle glaucoma (Regardless of Intraocular pressure)

• Previous history of topical beta-blocker use and insufficiently controlled IOP

Exclusion Criteria:

• Pigmentary or exfoliative glaucoma

• History of angle-closure or an occludable angle by gonioscopy

• Prior filtration or laser iridotomy

• Argon laser trabeculoplasty or Selective laser trabeculoplasty performed less than 6 months

• History or signs of chronic inflammatory eye disease, ocular trauma, or potentially progressive retinal disease